Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pentylenetetrazole - Balance Therapeutics

Drug Profile

Pentylenetetrazole - Balance Therapeutics

Alternative Names: BTD-001; carbon-14 (14C)-BTD-001; Pentetrazol; PTZ

Latest Information Update: 30 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Balance Therapeutics
  • Class Antihypotensives; Azepines; Nootropics; Respiratory stimulants; Sleep disorder therapies; Small molecules; Tetrazoles
  • Mechanism of Action Central nervous system stimulants; GABA-A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Hypersomnia; Narcolepsy
  • Phase I Down syndrome

Most Recent Events

  • 04 Jun 2018 Balance Therapeutics plans the phase II ARISE2 trial for Hypersomnia in USA in June 2018 (PO) (NCT03542851)
  • 29 May 2018 Balance Therapeutics initiates the phase II ARISE2 trial for Hypersomnia in USA (PO) (NCT03542851)
  • 12 Jul 2017 Balance Therapeutics completes a phase I trial in Down syndrome (In volunteers) in United Kingdom (PO) (NCT03150498)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top